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Influence of Continuous Venovenous Hemofiltration and Continuous
Venovenous Hemodiafiltration on the Disposition of Doripenem
Iolanda Cirillo,1* Nicole Vaccaro,1 Dainius Balis,1 Rebecca Redman,1 and Gary R. Matzke2
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey,1 and
School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia2
Received 2 August 2010/Returned for modification 17 October 2010/Accepted 26 December 2010
The pharmacokinetics, safety, and tolerability of a single 1-hour, 500-mg intravenous infusion of doripenem
were assessed in dialysis-dependent subjects with stage 5 chronic kidney disease undergoing continuous renal
replacement therapy (CRRT) via 12-hour continuous venovenous hemofiltration (CVVH) (n 6) or continuous
venovenous hemodiafiltration (CVVHDF) (n  5). Healthy volunteers were also assessed (n  12). Concen-
trations of doripenem and the primary metabolite doripenem-M-1 were measured in plasma and ultrafiltrate
or ultrafiltrate/dialysate by a validated liquid chromatography-tandem mass spectrometry method. In dialysis-
dependent subjects, levels of systemic exposure to doripenem and doripenem-M-1 were approximately 3- and
5-fold greater, respectively, than those in healthy subjects: for doripenem, 98 g  h/ml for CVVH and 77
g  h/ml for CVVHDF versus 32 g  h/ml for healthy subjects, and for doripenem-M-1, 24 g  h/ml for
CVVH and 22 g  h/ml for CVVHDF versus 4.7 g  h/ml for healthy subjects. The mean sieving coefficients
and saturation coefficients were >0.67 for both doripenem and doripenem-M-1. During CVVH and CVVHDF,
respectively, the percentages of administered doripenem dose removed were 38% and 29%, and clearances of
doripenem were 22 and 25 ml/min. Both CVVH and CVVHDF efficiently removed doripenem and doripenem-
M-1. Despite significant removal of drug by CVVH and CVVHDF, a single 1-hour, 500-mg doripenem infusion
produced significantly higher plasma concentrations of doripenem, higher systemic exposure (area under the
plasma concentration-time curve from time zero to 12 h after the start of infusion [AUC0–12]), and longer
half-life (t1/2) in subjects receiving CVVH or CVVHDF than in healthy volunteers. The recovery of drug in
ultrafiltrate and ultrafiltrate/dialysate and the enhanced rate of reduction of plasma concentrations indicate
that CVVH and CVVHDF significantly augmented residual total body clearance of doripenem in subjects
receiving CRRT. Doripenem dosage regimens for patients receiving CRRT thus need to be adjusted.
Doripenem is a synthetic, parenteral carbapenem with a
broad spectrum of microbiologic activity that has been ap-
proved in over 60 countries for the treatment of adults with
complicated intraabdominal infection, complicated urinary
tract infection, including pyelonephritis, and nosocomial pneu-
monia, including ventilator-associated pneumonia (24). Since
use of doripenem in critically ill patients in the intensive care
unit is anticipated, investigations have been conducted to as-
certain the pharmacokinetics of doripenem in patients with
various degrees of renal function, including those with end-
stage renal disease (ESRD) requiring dialysis (6). A critical
step in the development process was characterization of the
relationship between the pharmacodynamic response to dorip-
enem and the pharmacokinetic characteristics of the drug.
These studies revealed that, like other carbapenems, the phar-
macokinetic-pharmacodynamic index of doripenem that was
most closely associated with efficacy (90 to 99% reduction in
bacterial burden) against Gram-negative bacilli was the main-
tenance of plasma concentrations above the MICs (%TMIC)
(23).
Continuous renal replacement therapies (CRRTs), such as
continuous venovenous hemofiltration (CVVH) and continu-
ous venovenous hemodiafiltration (CVVHDF), are frequently
utilized to manage hemodynamically unstable patients, those
who are volume overloaded, and those who have acute kidney
insufficiency or acute kidney injury (5, 14, 19). Both of these
methodologies have been noted to significantly augment the
removal of extracellular fluid and waste products, such as urea
and creatinine, in those with impaired as well as normal renal
function. The total body clearance (CL) of many medications
has also been reported to be enhanced by CVVH and CV
VHDF (1, 12, 16, 21). The extent of the clinical impact is
primarily dependent on the ultrafiltration rate (QCRRT) and
the sieving coefficient (Sc) for patients receiving CVVH and
the combined ultrafiltration and dialysate flow rate (QUFD)
and the saturation coefficient (Sa) for those receiving CV
VHDF (12, 21).
The CRRT clearance during CVVH or CVVHDF (CLCRRT)
has been investigated for other carbapenems (imipenem, mero-
penem, ertapenem, and panipenem), and the clearances range
from 3.6 to 49.4 ml/min (4, 9–11, 13, 15, 17, 21, 22). In some cases,
the stability of the patients’ organ function status and consistency
of the delivery of the CRRT were poorly characterized (18).
These observations coupled with the broad range of the reported
values provided limited confidence for the extrapolation of these
findings to doripenem. This study was therefore designed to eval-
uate the clearance of doripenem and its primary inactive metab-
olite, doripenem-M-1, while performing controlled CVVH and
CVVHDF in dialysis-dependent subjects (DDS). This study en-
rolled subjects undergoing a stable hemodialysis regimen, be-
* Corresponding author. Mailing address: Clinical Pharmacology,
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.,
920 Route 202 South, Raritan, NJ 08869. Phone: (908) 218-6965. Fax:
(908) 203-1527. E-mail: icirillo@its.jnj.com.
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cause structured clinical studies requiring the application of stable
prescribed therapeutic CVVH or CVVHDF regimens may not be
clinically justifiable or feasible in critically ill patients.
MATERIALS AND METHODS
This prospective, open-label, single-dose pharmacokinetic study of doripenem
was conducted in dialysis-dependent subjects (DDS) with ESRD and healthy
adult volunteers from April to July 2008. The study protocol was reviewed and
approved by an independent ethics committee. The study was conducted in
accordance with the ethical principles of the Declaration of Helsinki and in
compliance with good clinical practices and all applicable regulatory require-
ments. All subjects participating in the study provided written informed consent
prior to study entry.
Subjects. (i) DDS with ESRD. Adult subjects with ESRD who had been
maintained on a standard hemodialysis regimen for at least 1 month preceding
study enrollment were eligible to participate in the study if they were between the
ages of 18 and 80 years, had a body mass index (BMI) between 18 kg/m2 and 38
kg/m2 (inclusive), weighed at least 50 kg, had a stable hematocrit of greater than
30% at screening, and had no recent history of vascular access complications.
Exclusion criteria included renal transplantation or renal carcinoma within 1 year
of screening, a relevant history of clinically significant drug allergy, hypersensi-
tivity, or intolerance to -lactam antibiotics, a history of hypersensitivity or
intolerance to heparin, prostacyclin, or citrate (trisodium citrate or anticoagulant
citrate dextrose solution A [ACD-A]), or a recent febrile illness. All DDS were
allowed to continue to receive concomitant prescribed medications to treat all
underlying disease states.
(ii) Healthy volunteers. Each healthy subject had normal renal function (es-
timated creatinine clearance between 70 and 150 ml/min) as calculated by the
Cockcroft-Gault formula (8) and was comparable to the DDS, for which they
served as a control, with respect to individual age (20 years) and weight
(30%). These subjects were all judged to be in good health based on a prestudy
medical history, physical examination, vital signs, electrocardiogram, and clinical
laboratory test results. They were not allowed to use any medication, except
acetaminophen (maximum of 3 doses of 500 mg per day, but no more than 3 g
per week) and hormonal contraceptive therapy, starting 21 days before and
continuing during the study.
Study design. Subjects who met eligibility criteria were admitted to one of the
two clinical research units, Virginia Commonwealth University and Orlando
Clinical Research Center, on the evening prior to doripenem administration to
confirm their eligibility and verify baseline observations and laboratory measure-
ments which were determined during the screening period. All subjects received
doripenem as a single 500-mg, 1-hour intravenous infusion into a forearm vein on
the morning of day 1 after an overnight fast. The DDS received doripenem
approximately 1 h after the start of their CRRT procedure. Doripenem was
infused in the contralateral arm from the dialysis access site or proximal to the
CRRT access site when the opposite arm was not possible.
CRRT technique. DDS were randomly assigned, using computer-based ran-
domization, to receive either CVVH or CVVHDF (6 subjects in each treatment
group). The assigned CRRT study procedure was administered on a day the
subject was not scheduled to receive the standard hemodialysis treatment. Thus,
each 13-h CRRT procedure was performed in addition to the patient’s regularly
scheduled hemodialysis treatments. Venous access was obtained by cannulation
of the patient’s hemodialysis arteriovenous fistula or polytetrafluoroethylene
graft. The inlet and outlet ports of the filter were connected to the patient and
the CRRT apparatus (Prisma; Fresenius Medical Care, New York, NY). This
device continuously monitored dialysate, blood, ultrafiltration, and replacement
fluid flow rates, as well as arterial and venous pressure, heparin infusion rate, and
total net volume removal rate. The same model/brand of hemofilter/dialyzer
(polyacrylonitrile AN69 0.9-m2 Prisma M100 dialyzer; Fresenius Medical Care,
New York, NY) was used for all CRRT procedures. The CRRT procedure was
initiated at a blood flow rate of 125 ml/min. Heparin was infused at a rate of
1,000 units per hour to maintain access and hemofilter patency. A bicarbonate-
based dialysate/replacement fluid was utilized in all patients (Prismanate BGK
2/0 dialysate at 5,000 ml plus 12.5 meq calcium chloride plus 7.5 meq potassium
chloride). In the CVVH procedure, the ultrafiltration removal rate and replace-
ment solution infusion rates were matched at a target of 2 liters per hour to
maintain the patient’s fluid status. For CVVHDF, the target ultrafiltrate (UF)
removal and dialysate flow rates were each 1 liter per hour. Ultrafiltrate losses
were replaced with replacement fluid at a rate of 1 liter per hour.
Pharmacokinetic assessments. (i) DDS with ESRD receiving CRRT. Serial
prefilter and postfilter blood samples (3 ml) were collected in heparinized
polypropylene or glass collection tubes by direct venipuncture or via an indwell-
ing catheter from a vein of the opposite arm from which doripenem was admin-
istered. No tubes with separation gel were used, and all samples were stored on
crushed ice immediately after collection. Samples for the determination of
plasma concentrations (CP) of doripenem and doripenem-M-1 were collected
during the CRRT treatment at the following time points relative to the start of
doripenem infusion: predose and at 0.25, 0.75, 1, 1.25, 1.5, 2, 4, 6, 8, and 12 h.
Venous blood samples were collected at 2, 6, 10, and 12 h after the end of the
CVVH or CVVHDF procedure. Samples were centrifuged for 10 min at 2,500 to
3,000 rpm to yield at least 1 ml of plasma. The plasma samples were frozen at
70°C or lower until analyzed for doripenem and doripenem-M-1 concentra-
tions.
Serial ultrafiltrate (UF) and ultrafiltrate/dialysate (UFD) samples for the
determination of doripenem and doripenem-M-1 concentrations were collected
at the following times relative to the start of the doripenem infusion: predose and
at 0.25, 0.75, 1, 1.25, 1.5, 2, 4, 6, 8, and 12 h. In addition, the total ultrafiltrate and
ultrafiltrate/dialysate fluid was collected during the following intervals: 0 to 4, 4
to 8, and 8 to 12 h. The total volume of fluid collected at each interval was
measured, and an aliquot was retained for the determination of doripenem and
doripenem-M-1 concentrations. The ultrafiltrate and ultrafiltrate/dialysate sam-
ples were frozen at 70°C or lower, where they remained until they were
transferred to the bioanalytical facility.
(ii) Healthy volunteers. All healthy subjects had venous blood samples col-
lected and processed for the determination of plasma concentrations of dorip-
enem and doripenem-M-1, as described above, immediately prior to the start of
the doripenem infusion and at the following times after the start of the infusion:
0.25, 0.75, 1, 1.25, 1.5, 2, 4, 6, 8, and 12 h.
Safety assessment. Safety was assessed throughout the study by evaluating the
incidence, severity, onset, resolution, and type of adverse events and their rela-
tionship to study drug, as well as changes in clinical laboratory test results,
physical examination findings, vital sign measurements, and need for medication
or other therapy.
Analytical procedures. Doripenem and doripenem-M-1 concentrations in
plasma (CP), UF (CUF), and UFD (CUFD) were quantified by validated assay
procedures using reversed-phase chromatography and detection by tandem mass
spectrometry (liquid chromatography-triple quadruple mass spectrometry [LC–
MS-MS]).
Plasma. Doripenem, doripenem-M-1, and the internal standard samples were
extracted from plasma (containing sodium heparin) by protein precipitation. The
peak areas were quantified using a Perkin-Elmer series 200 liquid chromato-
graph and an API 5000 series LC–MS-MS instrument (PE Sciex, Foster City,
CA) equipped with a Turbo ion spray in the positive ion mode. Calibration
curves were obtained by performing a linear regression (weighted 1/x2) on the
calibration standards, using Watson 7.0. Peak identification and integration were
done using Analyst v.1.4.1. The linear standard curve range was 0.1 to 50 g/ml,
with a lower limit of quantitation of 0.1 g/ml for both doripenem and dorip-
enem-M-1. The interassay precision (coefficient of variation [CV]) for dorip-
enem and doripenem-M-1 in plasma ranged from 4.2% to 16% and 3.7% to
8.1%, respectively, for quality control samples and 1.5% to 9.1% and 1.3% to
5%, respectively, for calibration standards.
UF and UFD. Doripenem, doripenem-M-1, and internal standard samples
were diluted with acetonitrile. The samples were vortex mixed and then analyzed
by reversed-phase high-performance liquid chromatography (HPLC) using an
Atlantis C18 column (Waters, Milford, MA) maintained at 30°C for doripenem
and 45°C for doripenem-M-1. The peak areas were quantified using a Perkin-
Elmer series 200 liquid chromatograph and an API 5000 series LC–MS-MS
instrument (PE Sciex, Foster City, CA) equipped with a Turbo ion spray in the
positive ion mode. The linear standard curve range was 0.1 to 50 g/ml, with a
lower limit of quantitation of 0.1 g/ml for both doripenem and doripenem-M-1.
The interassay precision (CV) for doripenem and doripenem-M-1 in dialysate
ranged from 1.3% to 2.3% and 1.5% to 5.2%, respectively, for quality control
samples and 0.7% to 4.6% and 0.8% to 4.2%, respectively, for calibration stan-
dards.
Pharmacokinetic analysis. (i) All subjects. Pharmacokinetic parameters for
doripenem and doripenem-M-1 were estimated from the observed individual
plasma (prefilter values were used for the subjects receiving CRRT) concentra-
tion-time data up to 12 hours after the start of the doripenem infusion, via
noncompartmental analysis with validated WinNonlin software version 5.2
(Pharsight Corporation). Plasma concentration values that were below the lower
limit of quantification were assigned a value of zero for all pharmacokinetic
assessments. The maximum observed plasma concentration (Cmax) and the time
the maximum plasma concentration was achieved (Tmax) were determined by
inspection of the plasma concentration-time profiles using WinNonlin. The ter-
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minal elimination rate constant (z) was determined by linear least-squares
regression analysis of the log-linear concentration-time profile from 1.5 to 12 h
for the subjects receiving CRRT or 1.5 to 8 h for the healthy volunteers. The
terminal elimination half-life (t1/2) for each subject was then calculated as 0.693/
z. The area under the plasma concentration-time curve from time zero to 12 h
after the start of doripenem infusion (AUC0–12) was calculated by linear trape-
zoidal approximation, and that from time zero to infinity (AUC0-) was calcu-
lated for the healthy volunteers as the sum of AUC0-12 and Clast/z, were Clast is
the last observed quantifiable concentration. The total body clearance (CL) of
doripenem was calculated as dose/AUC0-, while the apparent volume of distri-
bution at steady state (Vss) was calculated as MRT  CL, where MRT is mean
residence time. The renal clearance (CLR) of doripenem and doripenem-M-1
was calculated as Ae0–12 (the amount of doripenem or doripenem-M-1 excreted
into urine over the interval of 0 to 12 h) divided by AUC0-12. The nonrenal
clearance (CLNR) of doripenem was calculated as CL  (CLR  CLCRRT) for
subjects receiving CRRT and as CL  CLR for the healthy volunteers.
(ii) DDS receiving CRRT. The sieving coefficient (Sc) during CVVH and the
saturation coefficient (Sa) during CVVHDF of doripenem and doripenem-M-1
were calculated as Sc 	 CUF/CP and Sa 	 CUFD/CP, where ultrafiltrate concen-
tration (CUF), ultrafiltrate/dialysate concentrations (CUFD), and plasma concen-
tration (CP) were determined from simultaneously collected specimens at 1.25,
1.5, 2, 4, 6, 8, and 12 h after the start of the doripenem infusion. The cumulative
amount of doripenem and doripenem-M-1 excreted into UF or UFD (AeCRRT)
was calculated as the sum of the UF or UFD volume multiplied by the UF or
UFD concentration from each respective collection interval. The CVVH and
CVVHDF clearances (CLCRRT) of doripenem and doripenem-M-1 were calcu-
lated by multiplying the UF flow rate (QCVVH) or UFD flow rate (QCVVHDF) by
the average Sc or Sa, respectively, observed during each interval. QCVVH or
QCVVHDF was determined by dividing the volume of UF or UFD, respectively,
collected during each timed collection interval by the duration of the collection
interval (in hours). The contribution of CLCRRT to the CL of doripenem
(%CLCRRT) was calculated as CLCRRT divided by CL. Finally, urea clearance
(CLurea) was calculated as QCRRT  [(CUF/UFD)/CPmid], where CUF/UFD is the
urea concentration in UF or UFD during the 4- to 8-h collection interval, and
CPmid is the urea plasma concentration at the midpoint of the interval.
Statistics. Based on previous data in healthy subjects, the intersubject coeffi-
cient of variation (CV) for AUC and Cmax after a single 500-mg dose of dorip-
enem was estimated to be 30%. Assuming an intersubject CV of 35% for AUC
and Cmax of doripenem for dialysis-dependent subjects receiving CRRT, a sam-
ple size of 12 subjects was determined to be sufficient to estimate the mean AUC
and Cmax of doripenem for that group to fall within 80% and 125% of their true
values with 95% confidence.
Plasma concentrations and pharmacokinetic parameters of doripenem and its
metabolite doripenem-M-1 were summarized using descriptive statistics and are
expressed as means  standard deviations (SD) unless otherwise indicated.
Comparisons of the effect of CVVH versus that of CVVHDF on doripenem
and its metabolite were performed using Student’s t test. Analysis of variance
(ANOVA) was performed using SAS version 9.2 (SAS Institute, Cary, NC) on all
systemic pharmacokinetic parameters for all subjects, and for AUC0-12 and Cmax,
the values were natural log transformed before analysis was conducted. Each
ANOVA included calculations of the least-squares mean (LSM) for each group
and the standard errors associated with the differences between the CVVH,
CVVHDF, and healthy-volunteer groups. A P value of 0.05 or less was consid-
ered to indicate statistical significance.
RESULTS
A total of 25 subjects were enrolled and completed the
study, with 23 subjects included in the pharmacokinetic anal-
yses (11 subjects with ESRD receiving CRRT and 12 healthy
volunteers). Detailed information regarding patient demo-
graphics is given in Table 1. There were no statistically signif-
icant differences in gender, age, weight, or BMI score among
the dialysis-dependent subjects who received CVVH versus
those who received CVVHDF.
Doripenem pharmacokinetics. The plasma concentration-
time profiles of doripenem in the subjects receiving CRRT
(Fig. 1), after a single 500-mg doripenem infusion, were mark-
edly elevated compared to those in the healthy volunteers.
Doripenem AUC0–12 was approximately 3-fold or 2.5-fold
FIG. 1. Mean (SD) concentration-time profiles of doripenem. The
inset presents the concentration-time profile truncated to 12 h after the
start of doripenem infusion.
TABLE 1. Baseline demographic characteristicsa
Parameter
Result for CRRT subjects Result for
healthy subjects
(n 	 12)
CVVH subjects
(n 	 6)
CVVHDF subjects
(n 	 5)
Age (yr) 43.5 (6.89) 43.6 (9.45) 46.3 (5.14)
Weight (kg) 87.1 (29.5) 103 (17.4) 87.6 (9.82)
Height (cm) 174 (11.9) 178 (4.75) 174 (8.42)
BMI (kg/m2) 28.3 (6.14) 33.7 (3.69) 32.6 (3.64)
Gender
Male 3 (50) 5 (100) 9 (75)
Female 3 (50) 0 (0) 3 (25)
a Data are presented as means (standard deviations), except for gender data,
which indicate numbers (percentages) of patients.
VOL. 55, 2011 DORIPENEM DISPOSITION: IMPACT OF CVVH AND CVVHDF 1189
 o
n
 N
ovem
ber 24, 2015 by VIRG
INIA CO
M
M
O
NW
EALTH UNIV
http://aac.asm
.org/
D
ow
nloaded from
 
greater for those receiving CVVH (97.6 g  h/ml) or CV
VHDF (77.2 g  h/ml), respectively, than for the healthy sub-
jects (32.1 g  h/ml) (P 
 0.0001). The observed doripenem
plasma concentrations in the healthy subjects were similar to
data reported for other healthy subjects receiving doripenem
at 500 mg (7). The half-life of doripenem was approximately
4-fold longer for subjects receiving CVVH (mean [SD] of 4.24
[0.56] hours) and CVVHDF (3.87 [0.62] hours) than for
healthy subjects (1.29 [0.24] hours). Consistent with these dif-
ferences in exposure between the populations, the total body
clearance of doripenem was significantly reduced in subjects
receiving CVVH (4.94 [2.13] liters/h) and CVVHDF (5.89
[1.18] liters/h) compared to that in healthy subjects (15.95
[3.13] liters/h). However, the total and body weight-adjusted
Vss values were not significantly different among the three
groups of subjects (Table 2).
After termination of CRRT, mean doripenem plasma con-
centrations in the subjects receiving CRRT showed a slight rise
followed by a gradual decline until the end of the sampling
period (24 h), at which point low but quantifiable concentra-
tions were still detectable, 1.36 g/ml for CVVH subjects and
0.67 g/ml for CVVHDF subjects.
Doripenem CRRT pharmacokinetic parameters. Doripenem
plasma, UF, and UFD concentrations in the subjects who re-
ceived CVVH were similar over the entire sampling period to
concentrations in subjects who received CVVHDF (Fig. 1).
The mean (SD) Sc and Sa for doripenem during CVVH and
CVVHDF were 0.67 (0.149) and 0.75 (0.163), respectively,
indicating that doripenem is extensively removed by both pro-
cedures. These calculated values were consistent throughout
the sampling periods among all subjects, and no statistically
significant trends were evident (Fig. 3). The mean (SD)
AeCRRT (% per dose) for doripenem was slightly higher during
CVVH (27.5% [12.46%]) than during CVVHDF (20.5%
[3.99%]). The clearances of doripenem by CVVH and CV
VHDF were similar, at 22.2 (4.99) ml/min and 24.5 (5.03)
ml/min, respectively. The urea clearances by CVVH and CV
VHDF were similar, and these values did not significantly
differ from the CLCRRT of doripenem (Table 3).
TABLE 2. Systemic pharmacokinetic parameters of doripenem and doripenem-M-1a
Drug and parameter
Result for CRRT subjects
Result for healthy
subjects (n 	 12) P value
d
CVVH subjects
(n 	 6)
CVVHDF subjects
(n 	 5)
Doripenem
Tmax (h)
b 1.00 (0.97–1.03) 1.00 (0.75–1.00) 1.00 (1.00–1.00)
Cmax (g/ml) 24.1 (10.2) 18.9 (3.88) 17.9 (3.17) 0.125
AUC0–12 (g  h/
ml)
97.6 (33.4) 77.2 (14.3) 32.1 (6.08)c 
0.0001
AUC0– (g  h/ml) 114 (37.4) 87.5 (16.3) 32.5 (6.07) 
0.0001
t1/2 (h) 4.24 (0.562) 3.87 (0.622) 1.29 (0.233) 
0.0001
Vss (liter) 28.2 (14.1) 29.6 (6.36) 20.4 (3.77) 0.0657
Vss (liter/kg) 0.343 (0.199) 0.297 (0.0923) 0.233 (0.0294) 0.1441
CL (ml/min) 82.4 (35.5) 98.2 (19.8) 265 (52.1) 
0.0001
CL (liter/h) 4.94 (2.13) 5.98 (1.19) 15.9 (3.13) 
0.0001
CLR (liter/h) NA
e NA 9.20 (1.52)
CLNR (liter/h) 3.58 (2.33) 4.22 (0.818) 6.73 (2.02) 0.0097
Doripenem-M-1
Tmax (h)
b 1.00 (0.97–1.03) 1.00 (0.75–1.00) 1.00 (1.00–1.00)
Cmax (g/ml) 3.02 (0.818) 2.87 (1.33) 1.80 (0.366) 0.0670
AUC0–12 (g  h/
ml)
24.4 (4.58) 21.8 (6.63) 4.73 (0.955)c 
0.0001
AUC0– (g  h/ml) NA NA 5.22 (1.00)
t1/2 (h) NA NA 2.15 (0.282)
CLNR (liter/h) NA NA 14.2 (4.64)
a Data are presented as means (SD) unless otherwise noted.
b Median (range).
c Values represent the last quantifiable AUC0-12 (AUClast); median time of last quantifiable concentration (tlast) value, 8.00 h (range, 6.00 to 12.00).
d ANOVA (SAS 9.2) with the SHEFFE option was used, and P values represent comparisons between the healthy subjects and the two CRRT groups.
e NA, not assessable.
TABLE 3. Clearance of doripenem and doripenem-M-1 by CVVH
and CVVHDFa
Drug/product and
parameter
Result for CVVH
subjects (n 	 6)
Result for CVVHDF
subjects (n 	 5) P value
Doripenem
QCRRT (liter/h) 1.99 (0.0272) 1.96 (0.0487) 0.2967
Sc or Sa 0.67 (0.15) 0.76 (0.16) 0.4119
AUC0–12 (g  h/ml) 63.5 (30.7) 53.6 (11.4) 0.5143
AeCRRT (% per dose) 27.5 (12.5) 20.5 (3.99)b 0.3213
CLCRRT (ml/min) 22.2 (4.99) 24.5 (5.03) 0.6254
%CLCRRT 32.0 (15.2) 25.4 (5.06) 0.2795
Doripenem-M-1
Sc or Sa 0.82 (0.11) 0.93 (0.17) 0.4119
AUC0–12 (g  h/ml) 18.7 (4.10) 18.9 (4.90) 0.2094
AeCRRT (% per dose) 10.1 (3.82) 8.44 (1.65)b 0.9571
CLCRRT (ml/min) 27.1 (3.59) 30.3 (5.00) 0.2515
Urea
CLurea (ml/min) 26.8 (6.22) 26.7 (8.33) NAc
a Data are presented as means (SD) unless otherwise noted.
b n 	 4.
c NA, not assessable.
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Doripenem-M-1 pharmacokinetics. The maximum dorip-
enem-M-1 concentrations were similar, but the AUC of dorip-
enem-M-1 was significantly greater in subjects receiving CRRT
than in healthy subjects (Table 2). Plasma concentrations in
the elimination phase for subjects receiving CRRT decreased
at a lower rate than those for healthy subjects and did not
return to baseline by the end of the CRRT procedure (mean
concentrations, 1.61 g/ml [CVVH] and 1.29 g/ml [CVVHD
F]). After termination of CRRT, doripenem-M-1 plasma con-
centrations rebounded and remained above those observed at
the end of CRRT for the subsequent 12-hour sampling period
for subjects receiving CVVH or CVVHDF. The terminal elim-
ination half-life thus could not be reliably estimated for dorip-
enem-M-1 (Table 2).
Doripenem-M-1 CRRT pharmacokinetic parameters. Dorip-
enem-M-1 exposure in plasma during the CRRT procedure,
AUC0–12, was approximately 5-fold greater for the DDS (24.4
[4.58] g  h/ml during CVVH and 21.8 [6.63] g  h/ml during
CVVHDF) than for the healthy subjects (4.73 [0.96] g  h/ml)
(Fig. 2). The mean (SD) Sc and Sa for doripenem-M-1 during
CVVH and CVVHDF, respectively, were 0.817 (0.109) and
0.928 (0.174), indicating that doripenem-M-1 is extensively re-
moved by both procedures. These calculated values were con-
sistent throughout the sampling periods among all subjects,
and no statistically significant trends were evident (Fig. 3). The
mean (SD) AeCRRT (% per dose) for doripenem-M-1 was
slightly higher during CVVH (10.1% [3.82%])than during CV
VHDF (8.44% [1.65%]). The clearances of doripenem-M-1 by
CVVH and CVVHDF were similar, i.e., 27.1 (3.59) versus 30.3
(4.97) ml/min, respectively (Table 3).
Safety and tolerability. Treatment-emergent adverse events
were reported in 6 subjects: 3 healthy volunteers, 2 subjects
receiving CVVH, and 1 subject receiving CVVHDF. All of
these events were either mild or moderate in severity, and all
resolved by the end of the study. Three events, acute pancre-
atitis, acute abdominal pain, and hyperkalemia, were assessed
by the investigator as related to study drug. The event of acute
pancreatitis was reported on day 1 in a healthy volunteer,
resolved within 2 days, and was confounded by predisposing
conditions, including the possibility of a preexisting biliary
stone in a middle-aged woman with a BMI of 30.5 kg/m2 and
a history of hypercholesterolemia. The abdominal pain, de-
scribed as stomach cramps, occurred in a healthy male volun-
teer on day 1 and resolved spontaneously after 2 h. The event
of hyperkalemia was reported the day after study drug admin-
istration in a subject with ESRD with a medical history of
hyperkalemia. There were no deaths or serious adverse events
reported in the study.
DISCUSSION
The disposition of several carbapenems during CRRT has
been reported in single case reports or as a series of clinical
cases. Unfortunately, it is difficult, if not impossible, to control
the variables that may affect the clearance of carbapenems in
acutely ill patients. In this study, we prospectively measured
the systemic pharmacokinetics of doripenem and its primary
metabolite, doripenem-M-1, in DDS with ESRD undergoing a
session of CRRT. The mean CL and CLNR in these subjects
were similar to those in previous reports of subjects with
ESRD (6) and significantly lower than values observed in
healthy subjects (7). No significant differences in Vss were
noted. The impacts of two CRRT procedures, CVVH and
CVVHDF, on the disposition of doripenem and doripenem-
M-1 were also rigorously assessed. The mean Sc and Sa for
doripenem were comparable with those from previous reports
of imipenem and meropenem, in which the same hemofilter
was used (10, 13, 21). The CLCRRT of doripenem accounted
for 25 to 32% of the observed CL, and the mean values ranged
from 82 to 92% of simultaneous CLurea values, clearly indicat-
ing that either mode of CRRT has a marked effect on the
disposition of doripenem, which needs to be accounted for
with an increase in the daily doripenem dosage.
FIG. 2. Mean (SD) concentration-time profiles of doripenem-M-1.
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Many investigations of the pharmacokinetics of carbapen-
ems in critically ill individuals have been published in the last
10 to 15 years. The results of these investigations suggest that
there is marked variability between the agents within the class
and that critical illness and/or acute impairment of kidney
function is associated with a reduction in renal, as well as
nonrenal, clearance. The reduction in renal clearance of imi-
penem and meropenem is correlated with the patient’s degree
of residual renal function and independent of the duration of
the renal injury, i.e., whether the patient has acute or chronic
kidney disease. The reduction in nonrenal clearance of these
agents in subjects with acute impairment of kidney function is
significant relative to clearance in those with normal renal
function, but clearance is not as low as the values which have
been observed in subjects with ESRD who are dialysis depen-
dent. The renal and nonrenal clearance of doripenem in stable
chronic kidney disease patients, and those who are dialysis
dependent, has been noted to be lower than that observed in
healthy subjects; the results of these investigations can be uti-
lized to estimate the clearance of doripenem (6, 7).
Continuous replacement renal therapies have emerged as
the foundational renal replacement therapies for the critically
ill patient (5, 19). CVVH, as the preferred therapy for the
management of fluid-overloaded patients and at ultrafiltration
rates greater than 1 liter/h, has also proven to be an efficient
means of removing accumulated waste products. CVVHDF
augments convection with diffusion and as a result is consid-
ered by some to be the most efficient method of CRRT. In
clinical practice, these therapies are tailored to the individual
patient’s needs by modification of the blood flow and ultrafil-
tration, dialysate, and replacement fluid flow rates, as well as
the hemofilter or dialyzer. Results of recent investigations sug-
gest that although the achieved clearances of urea, a marker of
renal insufficiency and CRRT efficiency, may vary 2- to 3-fold,
the delivery of an increased therapeutic regimen was not as-
sociated with an improvement in clinical outcomes (2, 20).
The influences of CRRT on the removal of drugs have also
been noted to be markedly variable, although there is a clear
trend in the last 10 to 15 years toward higher clearances with all
agents that have been evaluated throughout this time period
(3, 9, 12, 21). The clearances of imipenem by CVVH ranged
from 6.5 to 13.3 ml/min in the 1990s and have increased to 22.9
to 36.0 ml/min during the last decade (9, 10, 21). This increase
is in part due to the utilization of larger-surface-area hemofil-
ters and higher ultrafiltration rates. The CVVHDF clearance
of imipenem has generally been greater than that observed
with CVVH; values have ranged from 18.7 to 57 ml/min, with
higher values being observed in patients who had greater QUFD
rates (9, 10, 21).
The disposition of meropenem has been evaluated exten-
sively in critically ill patients with creatinine clearances ranging
from 0 to 118 ml/min (13, 15, 17, 21). The total body clearances
reported by the nine investigative teams which have assessed
the influence of CVVH and/or CVVHDF vary widely (52 to
1,064 ml/min) and thus are relatively noninformative in terms
of application of the data to prospective patient care situations.
Focusing on those studies in patients with CLCR less than 70
ml/min dramatically reduces the variability in CL, to 52 to 143
ml/min (13, 17, 21). The mean nonrenal clearances from a
subgroup of 5 investigations of 38 patients ranged from 35 to
59 ml/min and are comparable to the values observed in indi-
viduals with normal renal function (Table 2). The CRRT pro-
cedure clearances are higher with CVVHDF than with CVVH,
and when the same hemofilter was utilized (AN69 with a sur-
face area of 0.9 m2), the values ranged from 27.0 to 38.9 ml/min
and 17.2 to 27.0 ml/min, respectively. The mean (SD) satura-
tion and sieving coefficients derived from these investigations
were less variable, 0.92 (0.05) and 0.74 (0.13), respectively, and
thus these parameters may be the most useful measure of
CRRT efficiency for prospective utilization.
Since the dialysis-dependent subjects evaluated in this study
had chronic renal disease and were not acutely or critically ill
but were anuric (n	 9) or had minimal residual renal function
(urine output less than 300 ml/day) (n 	 3), the systemic
pharmacokinetics of doripenem were expected to be, and were,
FIG. 3. Mean (SD) sieving coefficients and saturation coefficients
versus time.
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similar to previous observations in ESRD patients (Fig. 3). The
ability to maintain constant CVVH and CVVHDF procedures
throughout the observation period facilitated the rigorous
characterization of the clearance, Sc, and Sa of doripenem by
these two CRRTs. The doripenem Sc and Sa were stable over
the 12-h observation period and were consistent with previous
reports from other evaluation of carbapenems using the same
hemofilter. CLCVVH and CLCVVHDF were in the range of val-
ues reported for imipenem and meropenem when a similar
CRRT prescription was delivered. This information provides
clinicians with a sound foundation upon which to plan the
optimal dosage regimen for doripenem in critically ill patients
receiving CRRT.
The primary challenge to the clinician’s determination of the
optimal individualized dosage regimen is thus the broad range
of residual renal and other organ functions that one may en-
counter in the critically ill patient population. Indeed, the
composite organ function of one critically ill population may
bear little resemblance to that of another population. The
clinician is thus faced with the need to evaluate and quantify
the functionality of each relevant organ system, as well as the
influence of therapeutic interventions, such as CRRT, to arrive
at the optimal dosage regimen for the patient. This investiga-
tion provides the foundational knowledge of the influence of
CVVH and CVVHDF on the disposition of doripenem, which
can be used to guide the initiation of therapy and to perform
additional analysis to establish an optimal dosage regimen for
patients treated with doripenem and undergoing these modal-
ities of CRRT.
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